Login to Your Account



Biolipox Raises $41M To Advance Preclinical Inflammation Programs

By Cormac Sheridan


Wednesday, January 12, 2005
Biolipox AB, a firm developing anti-inflammatory drugs based on its knowledge of arachidonic acid metabolic pathways, disclosed Monday that it raised $41 million in a Series C round led by Scandinavian Life Science Venture. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription